# Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation

Study · id `cardio:ct-nct05797519` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05797519](<https://clinicaltrials.gov/study/NCT05797519>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05797519

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05797519. Allocation not applicable; no masking; primary purpose treatment. Start 2023-03-01 (actual); primary completion 2026-12-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05797519, source copy `cardio:ctgov-nct05797519-2026-08-13`, retrieved 2026-10-26)
- Started: 2023-03-01 (actual) (ClinicalTrials.gov record NCT05797519, source copy `cardio:ctgov-nct05797519-2026-08-13`, retrieved 2026-10-26)
- Primary completion: 2026-12-30 (anticipated) (ClinicalTrials.gov record NCT05797519, source copy `cardio:ctgov-nct05797519-2026-08-13`, retrieved 2026-10-26)
- Completion: 2030-12-30 (anticipated) (ClinicalTrials.gov record NCT05797519, source copy `cardio:ctgov-nct05797519-2026-08-13`, retrieved 2026-10-26)
- Countries: Australia; Austria; Belgium; Czechia; Denmark; Germany; Netherlands; New Zealand; Spain; Sweden; United Kingdom (ClinicalTrials.gov record NCT05797519, source copy `cardio:ctgov-nct05797519-2026-08-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05797519-2026-08-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation
- Acronym: VISTA
- Condition: Tricuspid Regurgitation
- Condition: Tricuspid Valve Disease
- Condition: Tricuspid Valvular Disorders
- Intervention (Device): VDyne Transcatheter Tricuspid Valve Replacement System
- Lead sponsor: VDyne, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry condition terms include this condition: Tricuspid regurgitation (`cardio:tricuspid-regurgitation`)

## Provenance

Content hash: 114e8cab554c1ed9e1a14a186b17b5bceadb0e0a83652bd3f622b6f496d5ab7d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
